Non-alcoholic fatty liver disease is the most rapidly growing form of liver disease and if left untreated can result in non-alcoholic steatohepatitis, ultimately resulting in liver cirrhosis and failure. Biliverdin reductase A (BVRA) is a multifunctioning protein primarily responsible for the reduction of biliverdin to bilirubin. Also, BVRA functions as a kinase and transcription factor, regulating several cellular functions. We report here that liver BVRA protects against hepatic steatosis by inhibiting glycogen synthase kinase 3␤ (GSK3␤) by enhancing serine 9 phosphorylation, which inhibits its activity. We show that GSK3␤ phosphorylates serine 73 (Ser(P) 73 ) of the peroxisome proliferator-activated receptor ␣ (PPAR␣), which in turn increased ubiquitination and protein turnover, as well as decreased activity. Interestingly, liver-specific BVRA KO mice had increased GSK3␤ activity and Ser(P) 73 of PPAR␣, which resulted in decreased PPAR␣ protein and activity. Furthermore, the liverspecific BVRA KO mice exhibited increased plasma glucose and insulin levels and decreased glycogen storage, which may be due to the manifestation of hepatic steatosis observed in the mice. These findings reveal a novel BVRA-GSK␤-PPAR␣ axis that regulates hepatic lipid metabolism and may provide unique targets for the treatment of non-alcoholic fatty liver disease.
steatosis, which causes the liver to be vulnerable to any hit that may follow, including increased oxidative stress and inflammation, thereby leading to hepatocyte injury and progression to NASH, liver fibrosis, cirrhosis, and ultimately liver failure. Factors that regulate insulin sensitivity, as well as reduce oxidative stress, minimize the capacity of immune signaling during hepatic lipid accumulation and prevent liver injury. We recently showed that induction of the heme oxygenase system and production of the antioxidant, bilirubin, reduced hepatic steatosis and lowered blood glucose (4) .
The catabolism of heme from heme oxygenase produces biliverdin, which is reduced to bilirubin by biliverdin reductase (BVR), which exists as two isozymes: BVRA and BVRB (5) . BVRB is the fetal isoform responsible for the production of bilirubin IX␤ from biliverdin IX␤ (6) and is only produced during the first 20 weeks after gestation. BVRB is expressed in adult tissues, but little is known about its function after fetal production of biliverdin IX␤ has discontinued. The BVRA isoform is also expressed in adult tissues and is responsible for reducing biliverdin IX␣ to bilirubin IX␣. In addition to functioning as a biliverdin reductase, BVRA can also function as a kinase and transcription factor and modulate insulin receptor signaling (5, 7) . Despite the multiple functions of BVRA and bilirubin their roles, in protecting the liver from hepatic steatosis have yet to be established. We recently showed that BVRA-derived bilirubin IX␣ binds directly to the nuclear receptor transcription factor PPAR␣ to reduce adiposity and blood glucose (8) . This is the first known ligand function reported for bilirubin. Importantly, PPAR␣ expression (4, 9, 10) and bilirubin levels are decreased in the obese (4, 9 -11) . The main function of PPAR␣ is to reduce hepatic steatosis through the burning of fatty acids via the regulation of genes involved in the ␤-oxidation pathway. The activation of PPAR␣ has been demonstrated to play a significant role in the attenuation of hepatic steatosis (14 -16) . PPAR␣ is a phosphoprotein; however, the regulation of the protein by phosphorylation by specific kinases and phosphatases are largely unknown (17) . However, PPAR␥, which induces fat storage in adipocytes and liver, has been shown to be regulated by kinases (18) and at least one phosphatase (19) . Indeed, PPAR␥ induces hepatic steatosis (20) . The mediation of lipid and glycogen storage in the liver is a delicate balance of kinase and phosphatase signaling during fasting and refeeding, as well as in lipid overload in fatty liver development. One of the major kinases involved in the progression of fatty liver is glycogen synthase kinase 3␤ (GSK3␤), which inhibits glycogen storage by the inhibition of glycogen synthase 2 via phosphorylation of the protein (21, 22) . GSK3␤ activation plays a significant role in hepatic lipid accumulation and lipoapoptosis (23, 24) . Regulation of GSK3␤ activity primarily occurs through phosphorylation at serine 9 of the protein, and increased phosphorylation of GSK3␤ at this residue decreases kinase activity.
In this study, we show in vitro and in vivo that hepatic BVRA can preserve PPAR␣ activity by increasing the phosphorylation of serine 9 in GSK3␤. Furthermore, we show that GSK3␤ can increase phosphorylation of serine 73 in PPAR␣, which causes rapid protein turnover and decreased overall PPAR␣ activity. Our data show a relationship between BVRA, GSK3␤, and PPAR␣ in the regulation of hepatic lipid metabolism and opens new avenues for therapeutic targeting.
Results

Liver-specific Deletion of BVRA Reduces Hepatic Insulin
Signaling-BVRA is an important protein regulating insulin signaling (5, 7, 25) and directly binds to and enhances phosphorylation of AKT (5) and ERK (26) . The capacity of BVRA to regulate insulin signaling suggests a role in the management of diabetes; however, BVRA, to date, has not been studied in whole animals. We generated floxed BVRA mice and after crossing them to Alb-cre (B6.Cg-Tg(Alb-cre)21Mgn/J) mice, LBVRA-KO mice were developed (described in detail under "Experimental Procedures"). LBVRA-KO mice display decreased levels of BVRA mRNA and protein ( Fig. 1 , A-C), as well as significantly (p Ͻ 0.05) less BVR activity in the liver (Fig. 1D ). After LBVRA-KO mice were placed on a high fat diet, no differences in body weight, body composition, or plasma bilirubin levels were observed between the LBVRA-KO and flox control mice ( Fig. 1 , E-G). However, LBVRA-KO mice exhibited enhanced fasting hyperglycemia and hyperinsulinemia as compared with flox control mice ( Fig. 1 , H and I). Examination of insulin signaling pathways in the liver of LBVRA-KO found no differences in the levels of insulin receptor-␤ (IR␤) or the IR precursor ( Fig. 2A) . Interestingly, the levels of AKT phosphorylation (pAKT) were markedly decreased in LVBRA-KO livers compared with flox mice (Fig. 2B ). LBVRA-KO mice exhibited an alteration in the glucose but not insulin tolerance test as compared with flox mice (Fig. 2, C and D) . These results suggest that a liver-specific loss of BVRA promotes hepatic insulin resistance that, in turn, leads to increased plasma glucose and insulin levels, which most likely stemmed from reduced insulin signaling and not insulin receptor expression.
BVRA Regulates Hepatic Lipid Accumulation-The accumulation of lipids in the liver and the development of fatty liver lead to decreased hepatic insulin sensitivity, which affects whole body insulin turnover, thereby increasing systemic levels of insulin and glucose. High circulating insulin levels may also cause peripheral insulin resistance and glucose intolerance. Hepatic lipid accumulation in the LBVRA-KO and floxed mice was determined by Echo-MRI, hepatic triglyceride levels, and Oil Red O staining of tissues slices. Livers from LBVRA-KO mice had significantly (p Ͻ 0.05) higher lipid levels compared with flox mice as shown by liver weight, hepatic triglycerides, and Oil Red O staining ( Fig. 3 , A-C). Several studies show increased phosphorylated AMP-activated protein kinase signaling is protective against hepatic steatosis. AMPK is activated by a decrease in ATP and a rise in cellular AMP (27) (28) (29) , which lead to the phosphorylation of key enzymes that subsequently inhibit the synthesis of fatty acids and increase glucose uptake. Levels of phosphorylated AMPK were markedly decreased in LBVRA-KO mice compared with flox mice (Fig. 3D ). Development of hepatic steatosis is linked to de novo production of fatty acids controlled by fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). FAS is responsible for the production of long chain fatty acids that contribute to the triglyceride pool. Parallel with lipid accumulation, FAS was significantly increased in the liver of LBVRA-KO mice as compared with flox mice (Fig. 3E) . Similarly, LBVRA-KO mice exhibited a significant reduction in the levels of phosphorylated ACC ( Fig. 3F ), which indicates enhanced ACC activity. ACC catalyzes the first steps of lipid synthesis involving the carboxylation of acetyl-CoA to malonyl-CoA. These data demonstrate that the loss of hepatic BVRA resulted in an enhancement of proteins and signaling pathways involved in the synthesis of fatty acids, which contributed to hepatic steatosis.
BVRA Regulates GSK3␤ and Hepatic Glycogen Storage-Glycogen synthase is the key enzyme involved in the storage of glucose as glycogen in liver and muscle. Glycogen synthase 2 (GYS2) is the predominant isoform found in the liver that is responsible for glycogen production. Phosphorylation at serine 641 by GSK3␤ inhibits activity of GYS2 and causes decreased glycogen storage (21, 22) . Conversely, for glycogen storage, GSK3␤ is inhibited by phosphorylation of serine 9. GSK3␤ phosphorylation was measured by two methods: Western blotting and a phosphoserine 9 GSK3␤-specific ELISA. The levels of serine 9 phosphorylated GSK3␤ were significantly decreased in the liver of LBVRA-KO as compared with flox control mice ( Fig. 4A) , which indicates activation. The increased GSK3␤ activity in LBVRA-KO mice is supported by decreased liver glycogen stores, GYS2 mRNA, and increased levels of phosphorylated GYS2 when compared with flox mice (Fig. 4, B-D) .
These data demonstrate that BVRA decreases GSK3␤ activity to enhance glycogen storage.
BVRA Regulates PPAR␣ Expression and Activity in the Liver-Hepatic steatosis arises from increased synthesis of fatty acids or by decreasing the burning of fat (␤-oxidation). PPAR␣ also binds to the promoter of GYS2 to increase expression (30) , which together interacts to regulate glycogen storage and steatosis. PPAR␣ regulation of lipid accumulation derives mainly from carnitine palmitoyltransferase-1A (CPT1A) and fibroblast growth factor 21 (FGF21). CPT1A is the rate-limiting enzyme in mitochondrial fatty acid ␤-oxidation. PPAR␣, and regulated gene CPT1A, protein levels were significantly (p Ͻ 0.05) decreased in the liver of LBVRA-KO as compared with flox mice (Fig. 5, A and B) . The reduction in PPAR␣ activity was confirmed by examining the expression of several of its target genes in the liver (Fig. 5 , B and C). FGF21, a major PPAR␣ target gene whose hepatic expression and plasma levels were also significantly decreased in LBVRA-KO as compared with flox mice (Fig. 5D ). These data show that BVRA is a major regulator of ␤-oxidation by mediating PPAR␣ expression and activity.
GSK3␤ Regulates PPAR␣ Activity Predominately through Phosphorylation of Serine 73-To determine the effect of GSK3␤ on PPAR␣ expression and activity, we examined a series of experiments utilizing kinase assays, ubiquitination, and the minimal PPRE-3tk-Luc construct. PPAR␣ has four major structural domains, the A/B (activation factor), C (DNA binding domain), D, and E/F (ligand binding) domains, that harbor five potential GSK3 phosphorylation sites (serines 59, 73, 76, 89, and 163) that are conserved across mammalian species ( Fig. 6A ). In vitro kinase assays showed that GSK3␤, based on kinase level, directly phosphorylates PPAR␣ ( Fig. 6B ). To localize the sites within PPAR␣ directly phosphorylated by GSK3␤, in vitro kinase assays were performed with purified PPAR␣ domain proteins ( Fig. 6C ). Full-length PPAR␣ was a substrate for phosphorylation by GSK3␤; however, the A/B domain of PPAR␣ was a better substrate for GSK3␤ phosphorylation in this assay ( Fig. 6C ). No phosphorylation occurred in the C-domain, despite the fact that it contains a consensus GSK3 binding site. Furthermore, no phosphorylation was observed in the D and E/F domains of the PPAR␣ protein.
Mutational analysis of serine S59A, S73A, S76A, and S89A in the PPAR␣ protein revealed that serine 73 (Ser 73 ) was the primary site in the A/B domain phosphorylated by GSK3␤ (data not shown). To determine whether GSK3␤ mediates ubiquitination of PPAR␣ protein by increasing Ser 73 phosphorylation, we performed transfections with WT PPAR␣ or S73A PPAR␣ in the presence of GSK3␤, ubiquitin, or empty vector. The cells were treated with DMSO or WY-14643 in the presence of, MG132, a proteasome inhibitor. The co-expression of PPAR␣ and GSK3␤ dramatically increased the ubiquitination of PPAR␣ relative to receptor alone ( Fig. 6D) . A ligand-dependent increase in ubiquitination was observed with receptor alone (fifth and sixth lanes), but no appreciable difference in liganddependent ubiquitination was observed with the overexpression of GSK3␤ (seventh and eighth lanes). The overexpression of GSK3␤ with S73A PPAR␣ resulted in increased ubiquitination (tenth and eleventh lanes), but decreased ubiquitination of S73A PPAR␣ was seen relative to WT receptor (twelfth and thirteenth lanes) ( Fig. 6D ). To determine whether GSK3␤ mediates PPAR␣ activity, we overexpressed GSK3␤ in a concentration-dependent manner and measured PPAR␣-dependent activation of the minimal PPRE promoter luciferase activity (PPRE-3tk-luc). Increasing concentrations of GSK3␤ decreased PPAR␣ activation with ligand, which was not observed in the empty vector control (Fig. 6E ). However, a K85A kinase-dead mutation of GSK3␤ failed to attenuate PPAR␣-dependent activation of the PPRE promoter luciferase activity ( Fig. 6F ). Altogether, these data demonstrate that GSK3␤ affects the ubiquitination of PPAR␣ by increasing phosphorylation of Ser 73 in PPAR␣, which ultimately inhibits activity. 
LBVRAKO Mice Have Decreased PPAR␣ Expression and
Enhanced Serine 73 Phosphorylation in the Liver-To determine the role of serine 73 phosphorylation on PPAR␣ activity, we examined S73A PPAR␣, which should be resistant to GSK3␤-mediated phosphorylation. In addition, a serine to aspartic acid S73D PPAR␣ mutation was created to mimic constitutive GSK3␤-mediated phosphorylation. S73A PPAR␣ had significantly (p Ͻ 0.01) higher basal activity as compared with WT PPAR␣ (Fig. 7A ). However, no difference was observed with WY-14643-induced PPAR␣ activity. In contrast, S73D PPAR␣, that mimics hyperphosphorylation by GSK3␤ resulted in decreased basal and WY-14643-mediated activation of PPAR␣ activity (Fig. 7A ). To detect serine 73 phosphorylation of PPAR␣, a rabbit phospho-specific antibody (Ser(P) 73 PPAR␣-Ab) was generated. Specificity of Ser(P) 73 PPAR␣-Ab was determined by transfecting COS-7 cells with FLAG-tagged PPAR␣, followed by immunostaining with Ser(P) 73 PPAR␣-Ab and FLAG antibodies. As predicted, Ser(P) 73 PPAR␣-Ab detected PPAR␣ WT but showed no reactivity when blocked with the Ser(P) 73 peptide used to create the antibody (Fig. 7B ). Levels of phosphorylated serine 73 were determined in the liver of LBVRA-KO and flox mice using the Ser(P) 73 PPAR␣ specific antibody. The ratio of phosphorylated serine 73 to total PPAR␣ immunostaining significantly (p Ͻ 0.01) increased in LBVRA-KO mice as compared with flox mice (Fig. 7C ). The increase in phosphorylated Ser 73 PPAR␣ is consistent with decreased phosphorylation of Ser 9 GSK3␤ in the liver of LBVRA-KO mice. These data also demonstrate, for the first time, that BVRA regulates GSK3␤-mediated phosphorylation of PPAR␣, which significantly contributes to the control of hepatic lipid metabolism.
Discussion
We report here, for the first time, a new hepatic signaling paradigm for BVRA, which regulates steatosis by inhibition of GSK3␤ and activation of PPAR␣. There is insufficient knowledge of the role of BVRA in the regulation of hepatic lipid accumulation or in insulin signaling. However, the interaction between BVRA and AKT has been previously reported. The Maines laboratory (25) demonstrated BVRA mediates insulin signaling and glucose uptake in human skeletal muscle cells.
Other studies indicate suppression of BVRA by siRNA decreased pAKT in HK-2 proximal tubule epithelial human cells (31) and rat heart H9c2 cells (32) , suggesting that BVRA may positively affect glucose uptake. In this study, we show that the LBVRA-KO mice had significantly reduced phosphorylation of AKT in the liver and higher plasma glucose and insulin levels. LBVRA-KO mice also exhibited alterations in glucose tolerance tests (GTTs) but not insulin tolerance tests (ITTs), suggesting alterations in hepatic insulin sensitivity. Interestingly, the body weight, fat and lean mass, and plasma bilirubin levels were the same as observed in the floxed mice. However, the LBVRA-KO mice had more lipids in the liver. Lipid accumulation in the liver leads to hepatic insulin resistance that can manifest into peripheral insulin resistance and eventually noninsulin dependent type II diabetes mellitus. The increased expression of FAS and phosphorylated ACC in the LBVRA-KO mice, which are involved in fatty acid synthesis, correlates with the development of hepatic steatosis in response to high fat diet feeding. FAS can generate lipids that can act as intracellular signaling molecules that are capable of regulating genes involved in the oxidation of fatty acids and fat storage. ACC is the rate-liming enzyme that catalyzes lipids for synthesis involving the carboxylation of acetyl-CoA to malonyl-CoA, which is then used for the storage of fat. ACC activity is inhibited via phosphorylation by AMPK, which, along with PPAR␣, increases the burning of fat through the ␤-oxidation pathway. The phosphorylation of ACC and AMPK was significantly reduced in LBVRA KO mice, indicating reduced burning of fat through ␤-oxidation. PPAR␣ increases key regulators of ␤-oxidation, CPT1 and FGF21, which CPT1 binds to long chain fatty acids in the mitochondria for lipid metabolism. FGF21 is a hepatic hormone that decreases fat in liver and increases glucose uptake (4, 33-36). Indeed, the LBVRA-KO mice exhibited reduced levels of hepatic CPT1A and FGF21. Other PPAR␣ target genes GYS2, CD36, G6Pase, glucokinase, CYP2J6, and CYP4A12 were significantly reduced in the livers of the LBVRA-KO mice. Overall, the loss of hepatic BVRA resulted in a decrease in the pathway for fatty acid oxidation and glycogen storage, as well as an increase in fatty acid synthesis and marked hepatic steatosis that most likely contributed to the increased blood glucose and insulin levels.
Our study identifies a novel pathway by which BVRA can regulate hepatic PPAR␣ levels through the modulation of GSK3␤-mediated phosphorylation of Ser(P) 73 . BVRA has been recently shown to directly interact with GSK3␤ (37) . Our data demonstrate that BVRA prevents GSK3␤ phosphorylation of PPAR␣ at serine 73 to decrease ubiquitin-mediated degradation of the protein. GSK3␤ is implicated in fatty liver disease and apoptosis, and small molecule inhibitors of GSK3␤ are demonstrated to protect against obesity-induced hepatic steatosis (38 -41) . LBVRA-KO mice have lower GSK3␤ phosphorylation, which is indicative of kinase activation (21, 42) . GSK3␤ activation was also evident by the enhanced phosphorylation of GYS2 in the liver of LBVRA-KO mice. Interestingly, the LBVRA-KO mice also had enhanced phosphorylation of serine 73 in PPAR␣, as well as decreased PPAR␣ expression and activity. We show that the decline in PPAR␣ activity and expression was mediated by GSK3␤, which was most likely to reduce ␤-oxidation and glycogen storage pathways. The importance of Ser(P) 73 in PPAR␣ regulation is further established by our findings that a mutation of this serine residue to an alanine is resistant to GSK3␤-mediated phosphorylation and decreased the activity of the protein. In contrast, mutation of this residue to aspartic acid to mimic GSK3␤-mediated phosphorylation resulted in decreased PPAR␣ activity under basal conditions and response to WY-14643 treatment. Taken together, these data identify Ser(P) 73 of PPAR␣ as a GSK3␤ target that is inhibited by hepatic BVRA to regulate fatty acid metabolism in liver and enhance PPAR␣-mediated gene transcription of the ␤-oxidation pathway (Fig. 8 ).
Although we have identified a novel pathway by which BVRA can decrease hepatic steatosis via inhibition of GSK3␤ mediated phosphorylation of PPAR␣, this pathway may also impact lipid accumulation through the intracellular production of bil-irubin. Bilirubin is a powerful antioxidant molecule (43, 44) . In addition to being a potent antioxidant, bilirubin has anti-inflammatory properties and can serve to prevent other types of cell stressors, such as endoplasmatic reticulum stress (25) (26) (27) . Several studies demonstrate increased serum bilirubin levels are associated with decreased hepatic steatosis (45) (46) (47) . Despite these correlative studies, which show a protective effect of serum bilirubin on hepatic steatosis, the mechanism by which bilirubin offers this safeguard is not currently known. However, we recently identified bilirubin as a novel PPAR␣ agonist (8) . Interestingly, its precursor, biliverdin, does not bind PPAR␣ efficiently (8) . Acute treatment of mice with bilirubin resulted in an increased hepatic PPAR␣ target genes, including FGF21, which was not observed in the liver or plasma of PPAR␣ knock-out mice (8) . Our results here demonstrate that hepatocyte-specific deletion of BVRA decreases PPAR␣ activity in the liver through alterations in GSK3␤ activity; however, the loss of bilirubin-derived PPAR␣ signaling increased hepatic steatosis in mice fed a high fat diet cannot be ruled out. However, BVRA has a 2-fold protection mechanism against NAFLD and fatty liver disease: 1) production of bilirubin that functions as an antioxidant and PPAR␣ ligand and 2) BVRA activation of AKT and inhibition of GSK3␤ (Fig. 8) . The degree to which the loss of bilirubin production contributes to this phenotype will need to be examined in future studies.
In conclusion, NAFLD, caused by the high rate of obesity, is the most rapidly growing form of liver disease in the general population. Currently, there are no effective treatments for NAFLD, and if combined with an additional hit to the liver, it can progress to NASH and ultimately liver failure. We have identified a novel pathway by which BVRA regulates hepatic steatosis by regulating GSK3␤-mediated phosphorylation of Ser(P) 73 of PPAR␣, which increases protein degradation and loss of PPAR␣ signaling. Our results suggest that hepatic BVRA or BVRA-mediated bilirubin will increase the burning of fat and sensitization to insulin and glucose intolerance. The BVRA-AKT-PPAR␣ axis is a major signaling paradigm, preventing fatty liver disease and insulin resistance.
Experimental Procedures
Animals-The experimental procedures and protocols of this study conform to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center in accordance with the NIH Guide for the Care and Use of Laboratory Animals. All mice had free access to food and water ad libitum. Animal activity and grooming were monitored daily to assess overall animal health. The animals were housed in a temperature-controlled environment with 12 h dark-light cycle. BVRA conditional knock-out mice were generated from gene targeted embryonic stem cells purchased from the European Conditional Mouse Mutagenesis Program (EUCOMM, clone HEPD0510_3_B01) and injected into blastocysts. The stem cells contained an altered copy of the BVRA gene, in which exon 2 was flanked by loxP sites. The neomyocin/lacZ cassette was then removed by breeding to Flp (B6.Cg-Tg(Pgk1-FLPo)10Sykr/J) mice for one generation. The resulting offspring were then genotyped to confirm removal of the neo/lacZ cassette and backcrossed to C57BL/6J mice for four generations before being bred to homozygosity for the floxed BVRA allele. The floxed BVRA mice were crossed to mice expressing the Cre recombinase (B6.Cg-Tg(Alb-cre)21Mgn/J) specifically in the liver under the control of the albumin promoter (stock no. 003574; Jackson Labs, Bar Harbor ME) to create liver-specific BVRA knock-out mice (LBVRAKO). The studies were performed on 6-week-old male mice initially housed under standard conditions with full access to standard mouse chow and water. After this time, the mice were switched with full access to a 60% high fat diet (diet no. D12492; Research Diets, Inc., New Brunswick, NJ) for 12 weeks and allowed access to water.
Body and Liver Composition-Body composition changes were assessed at 4-week intervals throughout the study using magnetic resonance imaging (EchoMRI-900TM; Echo Medical System, Houston, TX). MRI measurements were performed in conscious mice placed in a thin-walled plastic cylinder with a cylindrical plastic insert added to limit movement of the mice. The mice were briefly submitted to a low intensity electromagnetic field where fat mass, lean mass, free water, and total water were measured. At the end of the experimental protocol, the mice were euthanized by overdose of isoflurane anesthesia; the liver and fat were removed, and fat and lean mass were measured.
Glucose and Insulin Tolerance Tests-For GTTs, the mice were subjected to fasting (ϳ8 h), and D-glucose (1 g/kg of body weight) was injected intraperitoneally. ITTs were conducted on fasted mice, and insulin (0.75 units/kg of body weight; Novolin human insulin) was injected intraperitoneally. Blood glucose was monitored at 0, 15, 30, 60, and 90 min after glucose or insulin injection.
Liver Triglyceride Measurement-Triglycerides were measured from 100 mg of liver tissue homogenized in 1 ml of 5% Nonidet P-40 in water. Homogenized tissues were then heated to 95°C for 5 min and then centrifuged (13,000 ϫ g) for 2 min. Tissue triglyceride levels were measured using a fluorometric assay kit according to the manufacturer's guidelines (PicoProbe triglyceride fluorometric assay kit; BioVision, Milpitas, CA). Tissue triglyceride levels were then normalized to the amount of starting tissues and expressed as mg of triglyceride/g of tissue weight. Samples from individual mice were run in duplicate and averaged, and the averages of individual mice were then used to obtain group averages.
Measurement of Hepatic Ser(P) 9 GSK3␤-Hepatic levels of Ser(P) 9 GSK3␤ were measured using a specific Ser(P) 9 ELISA kit according to the manufacturer's guidelines (Ser(P) 9 ; GSK3␤ ELISA kit; Enzo, Farmingdale, NY). Briefly, 50 mg of liver tissue was homogenized in 500 l of RIPA buffer supplemented with phosphatase and protease inhibitors. Homogenates were then centrifuged briefly, and the supernatants were collected. ELISA was performed on diluted supernatants according to the manufacturer's protocols. Samples from individual mice were run in duplicate and averaged, and the averages of individual mice were then used to obtain group averages.
Measurement of Plasma FGF21-Plasma levels of FGF21 were measured from 50 l of plasma using a specific mouse/rat FGF21 ELISA (quantikine ELISA; R & D Systems, Minneapolis, MN) according to the manufacturer's instructions. The FGF21 ELISA was calibrated with a standard curve derived from a mouse/rat FGF21 standard provided by the manufacturer. FGF21 levels were measured in duplicate from individual mice, and FGF21 levels were determined by measurement at 450 nm on a plate reader. The concentrations are expressed as ng/ml.
Immunofluorescence-Immunofluorescence for BVRA was performed on paraformaldehyde-fixed liver samples. Sections of liver (20 m) were cut, rinsed in PBS, and blocked in 5% normal donkey serum for 1 h at 4°C. The sections were then incubated with BVRA antibody in 5% normal donkey serum overnight at 4°C and then rinsed in PBS. BVRA was detected using a rabbit anti-BVRA antibody (ADI-OSA-450, 1:100; Enzo Life Sciences, Farmingdale, NY). Antibody labeling was visualized using a fluorescence-labeled donkey anti-rabbit Alexa 488 (A-21206, 1:1000; Invitrogen) secondary antibody. Following a final rinse in PBS and DAPI counterstaining, the samples were covered with Fluoromount-G mounting medium (Southern Biotech, Birmingham, AL) and coverslipped before imaging. All samples were examined using a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems, Buffalo Grove, IL).
Liver Oil Red O Staining-To determine the effects of treatment on hepatic lipid accumulation, the livers were mounted and frozen in Tissue-Tek O.C.T and sectioned at 10 m. Frozen sections were air-dried and fixed in 10% neutral buffered formalin. The sections were briefly rinsed in tap water followed by 60% isopropanol and stained for 15 min in Oil Red O solution. The sections were further rinsed in 60% isopropanol, and the nuclei were stained with hematoxylin followed by aqueous mounting and coverslipping. The degree of Oil Red O staining was determined at 40ϫ magnification using a color Axiocam 105 camera with Zen 2 software attached to a Zeiss Axioplan microscope. The images were analyzed using National Institutes of Health ImageJ software, and to ensure accuracy of measurement, six images of each animal were analyzed and averaged into a single measurement. The measurements were obtained from three individual animals/group. The data are presented as the averages Ϯ S.E. of the percentage of Oil Red O staining for each group.
Periodic Acid Schiff Staining for Glycogen-Formalin-fixed, paraffin-embedded liver sections were cut at 5 m and deparaffinized, followed by hydration. The sections were oxidized in FIGURE 8 . Diagram of hepatic BVRA signaling to reduce fatty liver and increase glycogen storage. BVRA reduces biliverdin to bilirubin, which binds to and activates the nuclear receptor PPAR␣ for the burning of fat by ␤-oxidation and storage of glycogen by increasing GYS2. Additionally, BVRA binds directly to AKT to increase phosphorylation, which inhibits GSK3␤ activity to increase glycogen and decrease lipid storage in the liver. The BVRA-AKT interaction also increases hepatic insulin sensitivity and glucose uptake. 0.5% periodic acid solution for 5 min, rinsed in distilled water, and stained in Schiff's reagent for 15 min. The sections were washed in tap water, and the nuclei were counterstained with hematoxylin, rinsed, dehydrated, and coverslipped with Eukitt (Electron Microscopy Sciences, Hatfield, PA). For analysis, two or three random fields/slide were taken from three liver samples from each group at magnification of 40ϫ on a Zeiss Axioplan microscope equipped with an Axiocam 105 color camera and Zen 2 software.
Fasting Glucose and Insulin-Following an overnight fast, a blood sample was obtained via orbital sinus under isoflurane anesthesia. Blood glucose was measured using an Accu-Chek Advantage glucometer (Roche Applied Science). Fasting plasma insulin concentrations were determined by ELISA (Linco Insulin ELISA kit) as previously described (48) .
Biliverdin Reductase Assay-Biliverdin reductase activity was measured using a modified assay (49) . Samples were homogenized in a potassium phosphate buffer (10 mM potassium phosphate, 25 mM sucrose, 1 mM EDTA, and 0.1 mM PMSF). Biliverdin reductase activity was then measured in 0.5 mg of protein homogenate in an assay buffer (50 mM Tris-base, 1 mM EDTA, pH 8.7, 1.2 mM NADPH, and 0.03 mM biliverdin). The activity assay was done in a final volume of 1 ml. The reactions were incubated in the dark for 15 min at 37°C following by a 5-min incubation in the dark at 95°C. Bilirubin levels in the assay samples were determined by spectroscopy at 468 nm using a standard curve of bilirubin IX␣ (50 -300 M). BVR activity was expressed as mol of bilirubin/min/mg of protein.
Promoter Reporter Assays and PPAR␣ Mutants Construct Generation-The Cos7 green kidney monkey cells used for the promoter assays were routinely cultured and maintained in DMEM containing 10% bovine calf serum or FBS with 1% penicillin-streptomycin. Expression vector for PPAR␣-3X-FLAG CMV was constructed as previously described1 (13) . The S73A and S73D PPAR␣ mutants were generated using QuikChange site-directed mutagenesis kit with the PPAR␣-3X-FLAG CMV plasmid according to the manufacturer's protocol (Stratagene, La Jolla, CA). The HA-tagged GSK3␤ WT and K85A pcDNA3 was a gift from Jim Woodgett (Addgene plasmids 14753 and 14755, respectively) (12) . PPAR␣ minimal promoter PPRE-3tkluciferase activity was measured by luciferase in the previous of PPAR␣ and/or GSK3␤, and pRL-CMV Renilla reporter for normalization to transfection efficiency. Transient transfection was achieved using GeneFect (Alkali Scientific, Inc.). 24-h posttransfected cells were treated for 24 h in dialyzed fatty acid free FBS and then lysed. The luciferase assay was performed using the Promega dual luciferase assay system (Promega, Madison, WI).
Quantitative Real Time PCR Analysis-Total RNA was harvested from WT and BVRA knock-out mice by lysing livers using a Qiagen Tissue Lyser LT (Qiagen) and then extraction by 5-Prime PerfectPure RNA tissue kit (Fisher Scientific). Total RNA was read on a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific), and cDNA was synthesized using a high capacity cDNA reverse transcription kit (Applied Biosystems). PCR amplification of the cDNA was performed by quantitative real time PCR using TrueAmp SYBR Green qPCR SuperMix (Alkali Scientific). The thermocycling protocol con-sisted of 5 min at 95°C, 40 cycles of 15 s at 95°C, and 30 s at 60°C and finished with a melting curve ranging from 60 to 95°C to allow distinction of specific products. Normalization was performed in separate reactions with primers to GAPDH mRNA.
Gel Electrophoresis and Western Blotting-Mouse tissues were flash frozen in liquid nitrogen during harvesting and stored at Ϫ80°C. For gel electrophoresis, 50 -100 mg of cut tissue was then resuspended in 3 volumes of CelLytic Buffer (Sigma C3228) plus 10% protease inhibitor mixture (P2714-1BTL; Sigma) and Halt phosphatase inhibitor mixture (PI78420; Fisher), then incubated on ice for 30 min followed by lysing the livers using a Qiagen Tissue Lyser LT (Qiagen), and then centrifuged at 100,000 ϫ g at 4°C. Protein samples were resolved by SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to Immobilon-FL membranes. The membranes were blocked at room temperature for 2 h in TBS (10 mM Tris-HCl, pH 7.4, and 150 mM NaCl) containing 3% BSA. Subsequently, the membranes were incubated overnight at 4°C with the following antibodies: PPAR␣ (sc-9000; Santa Cruz Biotechnology, Santa Cruz, CA), heat shock protein 90 (HSP90) (13119; Santa Cruz), serine 73 phospho-PPAR␣ (described below), insulin receptor ␤ (sc-711; Santa Cruz), GYS2 (sc-47109; Santa Cruz), GYS phosphoserine 641 (3891; Cell Signaling), AKT (9272S; Cell Signaling), phospho-AKT (4060S; Cell Signaling), AMPK (2532S; Cell Signaling), phospho-AMPK (2535S; Cell Signaling), FAS (3180S; Cell Signaling), phospho-ACC (3661S; Cell Signaling), GSK3␤ (9832S; Cell Signaling), phospho-GSK3␤ (9336S; Cell Signaling), and CPT1A (ab128568; Abcam). After three washes in TBS ϩ 0.1% Tween 20, the membrane was incubated with an infrared antirabbit (IRDye 800, green) or anti-mouse (IRDye 680, red) secondary antibody labeled with IRDye infrared dye (LI-COR Biosciences) (1:10,000 dilution in TBS) for 2 h at 4°C. Immunoreactivity was visualized and quantified by infrared scanning in the Odyssey system (LI-COR Biosciences).
Generation of Serine 73 Phospho-PPAR␣ Antibody-To generate a phosphospecific antibody to a peptide corresponding to serine 73 at the N terminus of PPAR␣, 15 amino acids with phosphorylated serine 73 (VITDTLpSPASSPSS-Cys) was synthesized and purified by Pacific Immunology (Ramona, CA). The Ser(P) 73 -PPAR␣ antibody was made as previously described in Ref. 13 . In brief, an N-terminal cysteine was added to the peptide as a linker, followed by conjugation to a peptide carrier protein keyhole limpet hemocyanin and adjuvant-based immunization in a female New Zealand White rabbit. Preimmune serum was collected before injecting the rabbits with Ser(P) 73 -PPAR␣ peptide conjugate. The rabbits were boosted 2 weeks after injection with the Ser(P) 73 -PPAR␣ peptide with complete Freund's adjuvant and subsequently boosted two more times with incomplete Freund's adjuvant every 2 weeks. Serum was collected at 2 months and analyzed via ELISA for Ser(P) 73 -PPAR␣ specific antibodies. Serum of high titer was obtained and subjected to one round of affinity purification using the Ser(P) 73 -PPAR␣ peptide.
In Vitro Kinase Assay-PPAR␣, PPAR␣ mutants, and PPAR␣ domains were expressed as maltose-binding protein (MBP) fusion protein in DH5␣ bacteria and purified using amylose resin (New England Biolabs) as described previously (16) . pMAL rPPAR␣ mutants were generated using a QuikChange site-directed mutagenesis kit according to the manufacturer's protocol (Stratagene). Phosphorylation of MPB-PPAR␣, MBP-PPAR␣ domains, and MPB-PPAR␣ mutants was performed by incubating 2 g of MBP-PPAR␣, 5 or 25 ng of active GSK3␤ (Upstate Biotechnology, Lake Placid, NY), and 1 Ci of [␥-32 P]ATP (PerkinElmer Life Sciences) in kinase reaction buffer (40 mM MOPS, pH 7.0, 1 mM EDTA) according to the manufacturer's protocol for 90 min at 30°C. The proteins were heated to 95°C for 3 min and were separated on an 8% Trisglycine gel, dried, and visualized by autoradiography (n ϭ 3 separate experiments).
Ubiquitination of PPAR␣-After transfection (V5-rPPAR␣, HA-ubiquitin, pcDNA3.1 GSK3␤, V5-rPPAR␣ S73A, or empty vector; plasmids are described below) recovery, Cos-1 cells were co-treated with 50 M WY-14643 ([4-chloro-6-(2,3-zylindino)-2-pyrimidinylthio] acetic acid, CAS no. 50892-23-4; BIOMOL International, Plymouth Meeting, PA) or 0.1% DMSO in the presence of 5 M MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal Z-LLL-CHO; Calbiochem, San Diego, CA) for 4 h. The cells were lysed in 1 ml of RIPA buffer supplemented with mammalian protease inhibitor mixture and 10 g/ml ␣-iodoacetamide (Calbiochem) on ice for 20 min. Equal amounts of protein (1.5 mg) were precleared with 50 l of protein G-Sepharose for 2 h before incubation with 75 l of protein G-Sepharose (Santa Cruz Biotechnology, Santa Cruz, CA) plus 1 l anti-V5 antibody (R960-25, 1:5000; Invitrogen) overnight at 4°C with rocking. Immune complexes were washed four times with RIPA buffer plus 10 g/ml ␣-iodoacetamide, and proteins were eluted from the resin with 2ϫ Tricine sample buffer, heated at 80°C for 5 min, and separated on an 8% Tricine gel. The proteins were transferred to Hybond-ECL nitrocellulose, and the membrane was boiled in water for 5 min, immediately put into 5% nonfat dry milk blocking buffer, and probed for ubiquitinated PPAR␣ using V5-HRP antibody (R96125, 1:5000; Invitrogen) for detection of mono-ubiquination and HA-antibody (SC-7392, 1:1000; Santa Cruz Biotechnology) for detection of polyubiquination via Western blotting with detection by the addition of [ 125 I]streptavidin (1:10,000; GE Healthcare) with n ϭ 3 separate experiments. Plasmids for PPAR␣ ubiquitination analysis are as follows: pcDNA3.1/ V5-His-rPPAR␣ (V5-rPPAR␣) was described previously (16), V5-rPPAR␣ S73A mutant was generated using a QuikChange site-directed mutagenesis kit according to the manufacturer's protocol (Stratagene), pcDNA3.1 GSK3␤ was from Curtis Omiecinski (Pennsylvania State University, University Park, PA), and HA-ubiquitin was from Dirk Bohmann (University of Rochester, Rochester, NY).
Statistical Analysis-The data were analyzed with Prism 6 (GraphPad Software) using analysis of variance combined with Tukey's post-test to compare pairs of group means or unpaired t tests. The results are expressed as means Ϯ S.E. Additionally, one-way analysis of variance with a least significant difference post hoc test was used to compare mean values between multiple groups, and a two-tailed, and a two-way analysis of variance was utilized in multiple comparisons, followed by the Bonfer-roni post hoc analysis to identify interactions. p values of 0.05 or smaller were considered statistically significant. 
